BioPharmSignal logoBioPharmSignal

Biotech News

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio (INAB)IN8bioEarnings

Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI”) nearly doubling median progression-free survival (“mPFS”) to 13.0 months

Related news

INABIN8bio2026-08-06 20:01 EST

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

INABIN8bio2026-07-09 12:00 EST

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

View all latest news

IN8bio

Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates...

Recent company news

INABIN8bio2026-08-10 20:01 EST

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INABIN8bio2026-08-06 20:01 EST

IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights

INABIN8bio2026-07-09 12:00 EST

IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma

INABIN8bio2026-06-03 12:30 EST

IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies

INABIN8bio2026-06-01 12:30 EST

IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026

Stock data

Close
1.28 USD
Market cap
14.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States